2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
Primary:* To investigate the safety and tolerability of the co-administration of GSK598809 at175 mg and ethanol in healthy volunteers.* To examine the potential pharmacokinetic interactions between GSK598809administered at 175mg and ethanol in…